Merck & Co and Pfizer join forces on diabetes pill

New Drug Approvals




Drug giants Merck & Co and Pfizer have formed a new alliance to jointly develop and commercialise the latter’s ertugliflozin for the treatment of type II diabetes.

The drug is an investigational oral sodium glucose cotransporter (SGLT2) inhibitor, which is on the verge of entering Phase III trials, scheduled for later this year.

read more

View original post


About luciavazine

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s